Document is current
Any future updates will be listed below
-
Authors
Petrazzini, Ben Omega https://orcid.org/0000-0001-9789-9371
Forrest, Iain S. https://orcid.org/0000-0002-5642-422X
Rocheleau, Ghislain https://orcid.org/0000-0002-9989-7553
Vy, Ha My T.
Márquez-Luna, Carla
Duffy, Áine https://orcid.org/0000-0001-9164-1003
Chen, Robert
Park, Joshua K.
Gibson, Kyle
Goonewardena, Sascha N.
Malick, Waqas A.
Rosenson, Robert S.
Jordan, Daniel M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35-GM124836)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL139865)
- License Information
-
More Information
Article History
Received: 25 January 2023
Accepted: 8 May 2024
First Online: 11 June 2024
Competing interests
: R.D. reports being a scientific cofounder, consultant and equity holder for Pensieve Health (pending) and being a consultant for Variant Bio, all not related to this study. R.S.R. reports research funding to his institution from Amgen, Arrowhead, Eli Lilly, Merck, NIH, Novartis, Novo Nordisk, Regeneron and 89Bio, consulting fees from Amgen, Avilar, CRISPER Therapeutics, Editas, Eli Lilly, Lipigon, New Amsterdam, Novartis, Precision Biosciences, Regeneron, UltraGenyx, Verve Therapeutics, nonpromotional honoraria from Meda Pharma, royalties from Wolters Kluwer (UpToDate) and stock holding in MediMergent, LLC. He reports patent applications on: methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device. EFS ID: 32278349. application no. (PCT/US2019/026364) (provisional); all unrelated to this study. The other authors declare no competing interests.
